- Home
- CEAD vs SLXN Comparison
CEAD vs SLXN Comparison
Compare CEAD & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEAD
- SLXN
- Stock Information
- Founded
- CEAD 2009
- SLXN 2008
- Country
- CEAD United States
- SLXN Israel
- Employees
- CEAD N/A
- SLXN N/A
- Industry
- CEAD Industrial Machinery/Components
- SLXN
- Sector
- CEAD Industrials
- SLXN
- Exchange
- CEAD Nasdaq
- SLXN NYSE
- Market Cap
- CEAD 6.4M
- SLXN 7.6M
- IPO Year
- CEAD N/A
- SLXN N/A
- Fundamental
- Price
- CEAD $7.23
- SLXN $1.28
- Analyst Decision
- CEAD
- SLXN Strong Buy
- Analyst Count
- CEAD 0
- SLXN 1
- Target Price
- CEAD N/A
- SLXN $9.00
- AVG Volume (30 Days)
- CEAD 5.8K
- SLXN 31.1M
- Earning Date
- CEAD 03-27-2025
- SLXN 02-21-2025
- Dividend Yield
- CEAD N/A
- SLXN N/A
- EPS Growth
- CEAD N/A
- SLXN N/A
- EPS
- CEAD N/A
- SLXN N/A
- Revenue
- CEAD N/A
- SLXN N/A
- Revenue This Year
- CEAD N/A
- SLXN N/A
- Revenue Next Year
- CEAD N/A
- SLXN N/A
- P/E Ratio
- CEAD N/A
- SLXN N/A
- Revenue Growth
- CEAD N/A
- SLXN N/A
- 52 Week Low
- CEAD $5.60
- SLXN $0.21
- 52 Week High
- CEAD $11.04
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- CEAD 43.05
- SLXN N/A
- Support Level
- CEAD $7.21
- SLXN N/A
- Resistance Level
- CEAD $7.80
- SLXN N/A
- Average True Range (ATR)
- CEAD 0.23
- SLXN 0.00
- MACD
- CEAD -0.06
- SLXN 0.00
- Stochastic Oscillator
- CEAD 9.81
- SLXN 0.00
About CEAD CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.